Cibus, Inc. (CBUS)

Market Cap	117.39M
Revenue (ttm)	4.15M
Net Income (ttm)	-445.40M
Shares Out	29.57M
EPS (ttm)	-21.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	142,214
Open	4.300
Previous Close	4.340
Day's Range	3.940 - 4.400
52-Week Range	2.858 - 23.180
Beta	1.79
Analysts	Strong Buy
Price Target	22.83 (+475.06%)
Earnings Date	Nov 7, 2024

About CBUS

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 183
• Stock Exchange: NASDAQ
• Ticker Symbol: CBUS
• Website: https://www.cibus.com

Financial Performance

In 2023, Cibus's revenue was $1.82 million, an increase of 1057.32% compared to the previous year's $157,000. Losses were -$267.63 million, 1484.4% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CBUS stock is "Strong Buy." The 12-month stock price forecast is $22.83, which is an increase of 475.06% from the latest price.

Price Target

$22.83

(475.06% upside)

Analyst Consensus: Strong Buy